The PD-1 and PD-L1 inhibitor market produces drugs that help boost the immune system's ability to fight cancer cells by blocking proteins called PD-1 and PD-L1. These drugs are widely used for cancer treatment indications like melanoma, lung cancer and lymphoma.
The global PD-1 And PD-L1 Inhibitor Market is estimated to be valued at US$ 39.83 Bn in 2024 and is expected to exhibit a CAGR of 7.8% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends: The approval of PD-1 and PD-L1 inhibitors for new cancer treatment indications has accelerated the market growth over the past few years. Regulatory approvals for drugs like Keytruda, Opdivo and Tecentriq to treat cancers of kidney, liver, bladder and other organs have expanded the eligible patient pool. As the eligible patient population increases, usage of these drugs is growing significantly. Additionally, combination therapies involving PD-1 and PD-L1 inhibitors with other immuno-oncology drugs are showing promising results for several cancer types, which is further spurring revenue opportunities for market players.
Segment Analysis
The global PD-1 and PD-L1 Inhibitor market is dominated by the oncology segment. This is because PD-1 and PD-L1 inhibitors are majorly used to treat different types of cancers like melanoma, lung cancer, kidney cancer, Hodgkin's lymphoma etc. PD-1 and PD-L1 inhibitors help in improving the overall survival and progression-free survival rate in cancer patients.
Key Takeaways
The global PD-1 And PD-L1 Inhibitor Market Demand is expected to witness high growth during the forecast period of 2023 to 2030. The global PD-1 and PD-L1 Inhibitor Market is estimated to be valued at US$ 39.83 Bn in 2024 and is expected to exhibit a CAGR of 7.8% over the forecast period 2023 to 2030.
The North America region currently dominates the global PD-1 and PD-L1 Inhibitor market. This is attributed to the rising prevalence of cancer, rising healthcare expenditure, presence of major market players, and availability of advanced healthcare facilities in the region. However, the Asia Pacific region is expected to witness the fastest growth during the forecast period due to the rising healthcare awareness, improving healthcare infrastructure, and increasing disposable incomes in emerging economies like China and India.
Key players
Key players operating in the PD-1 and PD-L1 Inhibitor market are Sesajal S.A. de C.V., Olivado, Grupo Industrial Batellero S.A. de C.V, YASIN, Tron Hermanos SA de CV, The Village Press, Bella Vado, Chosen Foods LLC, and Storino's Quality Products. Sesajal S.A. de C.V. is one of the prominent players in the market with a strong geographic presence across various countries.
Explore more related article on this topic: https://www.pressreleasebulletin.com/the-pd-1-and-pd-l1-inhibitor-market-is-driven-by-rising-prevalence-of-cancer/
Comments
0 comment